Multiple Myeloma section

Multiple Myeloma News & Features

Panobinostat combination demonstrates benefit in relapsed/refractory multiple myeloma

Panobinostat combination demonstrates benefit in relapsed/refractory multiple myeloma

Patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone.

Injected immune cells found safe for patients with multiple myeloma

Injected immune cells found safe for patients with multiple myeloma

Researchers have reported safely using immune cells grown from patients' own bone marrow to treat multiple myeloma, according to clinical trial data.

Adding elotuzumab to myeloma treatment decreases risk of disease progression

Adding elotuzumab to myeloma treatment decreases risk of disease progression

Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.

Prior diagnosis of MGUS improves survival in patients with multiple myeloma

Prior diagnosis of MGUS improves survival in patients with multiple myeloma

Patients with multiple myeloma seem to have improves survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first.

Farydak (panobinostat) now FDA-approved for multiple myeloma

Farydak (panobinostat) now FDA-approved for multiple myeloma

Drug is now sanctioned for people who have received at least two prior standard therapies.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs